This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cardoso, F. Articles by Piccart-Gebhart, M. J. Search for Related Content PubMed PubMed Citation Articles by Cardoso, F. Articles by Piccart-Gebhart, M. J. Social Bookmarking                            What's this?

Clinical Application of the 70-Gene Profile: The MINDACT Trial

Fatima Cardoso, Laura Van't Veer, Emiel Rutgers, Sherene Loi, Stella Mook, Martine J. Piccart-Gebhart

From the Jules Bordet Institute, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, the Netherlands; and Peter MacCallum Cancer Centre, Melbourne, Australia

Corresponding author: M.J. Piccart-Gebhart, PhD, MD, Medical Oncology, Jules Bordet Institute, Blvd de Waterloo, 125, 1000 Brussels, Belgium; e-mail: martine.piccart{at}bordet.be

The 70-gene profile is a new prognostic tool that has the potential to greatly improve risk assessment and treatment decision making for early breast cancer. Its prospective validation is currently ongoing through the MINDACT (Microarray in Node-Negative Disease May Avoid Chemotherapy) trial, a 6,000-patient randomized, multicentric trial. This article reviews the several steps in the development of the profile from its discovery to its clinical validation.

Supported by the European Commission Framework Programme VI, the Breast Cancer Research Foundation, the European Breast Cancer Conference (EBCC) Breast Cancer Working Group, the Fondation Belge Contre Le Cancer, the Susan G. Komen for the Cure Foundation, Jacqueline Seroussi Memorial Foundation for Cancer Research, the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group, the Center of Biomedical Genetics, the Dutch Health Care Insurance Board, and the Dutch National Genomic Initiative Cancer Genomics Program.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. H. Barrios, C. Sampaio, J. Vinholes, and R. Caponero What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann. Onc., July 1, 2009; 20(7): 1157 - 1162. [Abstract] [Full Text] [PDF]

				J. Hugh, J. Hanson, M. C. U. Cheang, T. O. Nielsen, C. M. Perou, C. Dumontet, J. Reed, M. Krajewska, I. Treilleux, M. Rupin, et al. Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial J. Clin. Oncol., March 10, 2009; 27(8): 1168 - 1176. [Abstract] [Full Text] [PDF]

				N. S. Russell, I. H. Kunkler, G. van Tienhoven, P. A. Canney, J. Thomas, J. Bartlett, M. J. van de Vijver, Y. Belkacemi, J. R. Yarnold, and P. J. Barrett-Lee Postmastectomy Radiotherapy: Will the Selective Use of Postmastectomy Radiotherapy Study End the Debate? J. Clin. Oncol., February 20, 2009; 27(6): 996 - 997. [Full Text] [PDF]

				C. Sotiriou and L. Pusztai Gene-Expression Signatures in Breast Cancer N. Engl. J. Med., February 19, 2009; 360(8): 790 - 800. [Full Text] [PDF]

				M. Dowsett and A. K. Dunbier Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer Clin. Cancer Res., December 15, 2008; 14(24): 8019 - 8026. [Abstract] [Full Text] [PDF]

				M. J. Hassett, M. E. Hughes, J. C. Niland, S. B. Edge, R. L. Theriault, Y.-N. Wong, J. Wilson, W. B. Carter, D. W. Blayney, and J. C. Weeks Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer J. Clin. Oncol., December 1, 2008; 26(34): 5553 - 5560. [Abstract] [Full Text] [PDF]

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				M. J. Duffy and J. Crown A Personalized Approach to Cancer Treatment: How Biomarkers Can Help Clin. Chem., November 1, 2008; 54(11): 1770 - 1779. [Abstract] [Full Text] [PDF]

				E. J.T. Rutgers, L. Pusztai, and R. Bernards Are Short-Term or Long-Term Recurrence Rates More Important in Breast Cancer Screening? Ann Intern Med, September 2, 2008; 149(5): 357 - 357. [Full Text] [PDF]